Three new, independent directors join Cangene's board



    Listed TSX, Symbol: CNJ

    TORONTO and WINNIPEG, March 26 /CNW/ - Cangene Corporation today
announces that three new, independent directors have joined its board of
directors. Drs. Bruce Burlington, Philip Johnson and Scott Lillibridge will
join Cangene's board effective immediately. This addition brings Cangene's
board to 11 members, six of whom are independent. For the first time, the
majority of Cangene's directors will be independent of the Apotex Group,
Cangene's majority shareholder.
    "We are extremely pleased to attract new individuals of this calibre and
experience to our board," said Dr. John Langstaff, Cangene's president and
CEO. "Collectively they bring extensive experience in the U.S. regulatory
environment, government biodefence and infectious disease programs, and the
medical aspects of infectious diseases worldwide."
    Bruce Burlington, MD, age 59, received his medical degree from Louisiana
State University in 1976 after completing a B.A. in Economics and Psychology
at Louisiana Technical University in 1970. Additionally, he earned board
certifications following training at the University of Colorado in both
internal medicine and infectious disease. He joined the United States Food and
Drug Administration in 1981 where he spent 17 years in various roles,
including: Director, Division of Biological Investigational New Drugs in the
Center for Biologics Evaluation and Research; Acting Director in the Office of
Generic Drugs, Center for Drug Evaluation and Research; and Director of the
Center for Devices and Radiological Health. In 1999, he was recruited by Wyeth
Pharmaceuticals as Senior Vice President, Global Regulatory Affairs. He spent
nine years within the Wyeth organization and recently retired from his
position as Executive Vice President, Business Practices and Compliance.
    Philip R. Johnson, Jr., MD, age 53, received his undergraduate and
medical degrees from the University of North Carolina at Chapel Hill, followed
by pediatric residency and infectious disease training at Vanderbilt
University. After fellowship training, he worked at the National Institutes of
Health and Columbus Children's Hospital for 20 years before assuming his
current positions as Chief Scientific Officer and Executive Vice President at
The Children's Hospital of Philadelphia and Professor of Pediatrics at the
University of Pennsylvania School of Medicine. Over the last decade, Dr.
Johnson has focused on gene transfer technology for use in vaccine antigen
delivery, culminating in the development of a candidate HIV-1 vaccine that is
now in human clinical trials. Dr. Johnson has received numerous national
honors including election to the American Pediatric Society, being named a
Fellow of the American Association for the Advancement of Science, and being
named as a member the American Academy of Microbiology.
    Scott R. Lillibridge, MD, age 55, received his medical degree from the
Uniformed Services University of the Health Sciences in Bethesda, Maryland
after completing a BA in Environmental Health at East Tennessee State
University. Dr. Lillibridge has extensive training in epidemiology and public
health. His United States Public Health Service career is mostly identified
with the U.S. Centers for Disease Control and Prevention (CDC) where he
assumed many emergency responsibilities including Chief Medical Officer, U.S.
Office of Foreign Disaster Assistance and founding Director of the
Bioterrorism Preparedness and Response Program. He also served as Special
Assistant to the Secretary DHHS for National Security and Emergency Management
where he advised on issues related to bioterrorism and other public health
preparedness. After his federal career, he went on to found the Center for
Biosecurity and Public Health Preparedness at the University of Texas Health
Science Center Houston. In 2007, he and his entire team were recruited to the
Texas A&M Health Science Center where he has expanded his work related to
global health and security.

    About Cangene Corporation

    Cangene is one of Canada's largest and earliest biopharmaceutical
companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba.
Cangene has approximately 650 employees in eight locations across North
America. It operates three large manufacturing facilities--two in Winnipeg,
Manitoba and one in Baltimore, Maryland--where it produces its own products
and undertakes contract manufacturing for a number of companies. Cangene
operates three U.S. and one Canadian plasma-collection facilities. In
addition, it has a regulatory affairs, sales and investor relations office in
Toronto, Ontario (NOTE: this office moved in January 2008, the new address is
180 Attwell Drive, Suite 360, Toronto, ON, M9W 6A9; phone 416-675-8300; fax
416-675-8301).
    The Company uses patented manufacturing processes to produce
plasma-derived and recombinant therapeutic proteins. Cangene has five FDA
and/or Health Canada-approved products. In addition, the Company has several
more products in development at various stages. Three of Cangene's products
have been accepted into the U.S. Strategic National Stockpile--botulism
antitoxin, anthrax immune globulin and vaccinia immune globulin, a product
used to counteract certain complications arising from smallpox vaccination.
    Capitalizing on its drug manufacturing expertise, Cangene also operates a
significant contract research and manufacturing business using its Winnipeg
facilities and the resources of Baltimore, Maryland-based Chesapeake
Biological Laboratories, Inc. (a wholly owned subsidiary). An expansion in
2006 at the Winnipeg location increased the Company's capacity to fractionate
plasma to accommodate the growing manufacturing requirements. Cangene's
website, www.cangene.com, includes product and investor information, including
past news releases. Chesapeake's website is www.cblinc.com.

    Forward-looking information

    The reader should be aware that Cangene's businesses are subject to risks
and uncertainties that cannot be predicted or quantified; consequently, actual
results may differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or contribute to
such risks or uncertainties include, but are not limited to: the regulatory
environment including the difficulty of predicting regulatory outcomes;
changes in the value of the Canadian dollar; the Company's reliance on a small
number of customers including government organizations; the demand for new
products and the impact of competitive products, service and pricing;
availability and cost of raw materials, especially the cost, availability and
antibody concentration in plasma; fluctuations in operating results;
government policies or actions; progress and cost of clinical trials; reliance
on key strategic relationships; costs and possible development delays
resulting from use of legal, regulatory or legislative strategies by the
Company's competitors; uncertainty related to intellectual property protection
and potential cost associated with its defence; the Company's exposure to
lawsuits, and other matters beyond control of management.
    Risks and uncertainties are discussed more extensively in the MD&A
section of the Company's most recent annual report and annual information
form, which are available on the Company's website or on SEDAR at
www.sedar.com. Scientific information that relates to unapproved products or
unapproved uses of products is preliminary and investigative. No conclusions
can or should be drawn regarding the safety or efficacy of such products. Only
regulatory authorities can determine whether products are safe and effective
for the uses being investigated. Healthcare professionals are directed to
refer to approved labeling for products and not rely on information presented
in news releases. Drug names and prescribing information may differ in various
countries.

    The cautionary statements referred to above should be considered in
connection with all written or oral statements, especially forward-looking
statements, that are made by the Company or by persons acting on its behalf
and in conjunction with its periodic filings with Securities Commissions,
including those contained in the Company's news releases and most recently
filed annual information form. Forward-looking statements can be identified by
the use of words such as "expects", "plans", "will", "believes", "estimates",
"intends", "may", "bodes" and other words of similar meaning (including
negative and grammatical variations). Should known or unknown risks or
uncertainties materialize, or should management's assumptions prove
inaccurate, actual results could vary materially from those anticipated. The
Company undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable law.

    %SEDAR: 00002351E




For further information:

For further information: about Cangene Corporation, please contact Mike
Graham at (204) 275-4040 or by email at mgraham@cangene.com

Organization Profile

Cangene Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890